Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Proia

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2013
Network analysis identifies an HSP90-central hub susceptible in ovarian cancerHanqing Liu, Fang Xiao, Ilya G Serebriiskii, et al.
Plos One|May 3, 2011
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signalingDavid A Proia, Kevin P Foley, Tim Korbut, et al.
Investigational New Drugs|January 10, 2012
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsDavid A Proia, Jim Sang, Suqin He, et al.
Oncoimmunology|April 9, 2016
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancerChristine Mall, Gail D Sckisel, David A Proia, et al.
Plos One|January 19, 2012
Mitochondrial electron transport is the cellular target of the oncology drug elesclomolRonald K Blackman, Kahlin Cheung-Ong, Marinella Gebbia, et al.
Cell Stem Cell|February 8, 2011
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fateTheresa A Proia, Patricia J Keller, Piyush B Gupta, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney diseaseTamina Seeger-Nukpezah, David A Proia, Brian L Egleston, et al.
Cancer Discovery|April 8, 2014
Epithelial-to-mesenchymal transition activates PERK-eIF2α and sensitizes cells to endoplasmic reticulum stressYu-Xiong Feng, Ethan S Sokol, Catherine A Del Vecchio, et al.
Molecular Cancer Research : MCR|May 3, 2014
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolismJaime Acquaviva, Suqin He, Chaohua Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancerDavid A Proia, Chaohua Zhang, Manuel Sequeira, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2013
Network analysis identifies an HSP90-central hub susceptible in ovarian cancerHanqing Liu, Fang Xiao, Ilya G Serebriiskii, et al.
Plos One|May 3, 2011
Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signalingDavid A Proia, Kevin P Foley, Tim Korbut, et al.
Investigational New Drugs|January 10, 2012
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer modelsDavid A Proia, Jim Sang, Suqin He, et al.
Oncoimmunology|April 9, 2016
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancerChristine Mall, Gail D Sckisel, David A Proia, et al.
Plos One|January 19, 2012
Mitochondrial electron transport is the cellular target of the oncology drug elesclomolRonald K Blackman, Kahlin Cheung-Ong, Marinella Gebbia, et al.
Cell Stem Cell|February 8, 2011
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fateTheresa A Proia, Patricia J Keller, Piyush B Gupta, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 17, 2013
Inhibiting the HSP90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney diseaseTamina Seeger-Nukpezah, David A Proia, Brian L Egleston, et al.
Cancer Discovery|April 8, 2014
Epithelial-to-mesenchymal transition activates PERK-eIF2α and sensitizes cells to endoplasmic reticulum stressYu-Xiong Feng, Ethan S Sokol, Catherine A Del Vecchio, et al.
Molecular Cancer Research : MCR|May 3, 2014
FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolismJaime Acquaviva, Suqin He, Chaohua Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2013
Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancerDavid A Proia, Chaohua Zhang, Manuel Sequeira, et al.
Pageof 9